Deslorelin vs GHRP-6
A neutral, side-by-side comparison of two performance & growth hormone peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.
Deslorelin
Potent GnRH super agonist approximately 100× more potent than native GnRH. Used in veterinary medicine for estrus suppression and in human medicine for precocious puberty treatment. In research protocols, used for pituitary desensitization to reset the HPG axis or induce controlled medical suppression of sex hormone production.
Full profileGHRP-6
GHRP-6 is a first-generation synthetic hexapeptide GH secretagogue that strongly stimulates pituitary GH release via ghrelin receptor activation. It is one of the oldest and most well-studied GHRPs, with a large body of research spanning more than three decades. GHRP-6 produces significant GH pulses but is notable for powerfully stimulating appetite — a side effect that can be beneficial for those in a caloric deficit or disadvantageous for those managing body composition.
Full profile| Deslorelin | GHRP-6 | |
|---|---|---|
| Category | Performance & Growth Hormone | Performance & Growth Hormone |
| Also known as | SuvaPryn, Ovuplant, D-His6-Pro9-Et-GnRH | Growth Hormone Releasing Peptide-6, His-D-Trp-Ala-Trp-D-Phe-Lys-NH2 |
| Evidence | Research-stage | Preclinical only |
| Dosing range | 50mcg–200mcg mcg, Daily SC for continuous suppression; single or short course for pituitary reset | 100mcg–300mcg mcg, 1–3 times daily, on an empty stomach |
| Administration | Subcutaneous implant (veterinary), Subcutaneous injection | Subcutaneous injection, Intramuscular injection |
| Key side effects | Hot flashes, Bone density loss (prolonged suppression), Suppression of testosterone or estrogen, Mood changes, irritability | Strong increase in appetite (most common and notable), Elevated cortisol and prolactin at higher doses, Water retention / bloating, Fatigue at high doses |
| Cited sources | 2 references | 3 references |
Key differences
- Evidence level differs: Deslorelin is research-stage, while GHRP-6 is preclinical only.
- Administration: Deslorelin — Subcutaneous implant (veterinary), Subcutaneous injection; GHRP-6 — Subcutaneous injection, Intramuscular injection.
- Frequency: Deslorelin is typically Daily SC for continuous suppression; single or short course for pituitary reset; GHRP-6 is 1–3 times daily, on an empty stomach.
- Research depth: this profile cites 2 sources for Deslorelin vs 3 for GHRP-6.
How each works
Deslorelin
Deslorelin produces a robust initial LH/FSH surge (flare effect) followed by profound, sustained pituitary desensitization with continued exposure. This biphasic response is consistent across all high-affinity GnRH super agonists. The flare phase is exploited for reproductive timing in veterinary medicine; the desensitization phase creates the clinical suppression used in precocious puberty and research HPG axis reset protocols.
GHRP-6
Human studies confirm GHRP-6 robustly elevates GH within 15–30 minutes of injection, with effects diminishing toward baseline within 2–3 hours. Chronic use increases baseline IGF-1. Research also indicates mild stimulation of cortisol and prolactin, particularly at higher doses. Animal models have shown potential cardioprotective, hepatoprotective, and muscle-sparing effects, though human equivalents are not established.
This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.